Glioblastoma: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• MGMT 20
• EGFR 13
• IDH 10
• STAT3 3
• TP53 0
• AKT 0
• mTOR 1
• PI3K 1
• PD-1 7
• ERK 0
• PD-L1 5
• STING 0
• YAP 0
• B7-H3 7
• MAPK 0
• CTNNB1 0
• PARP 1
• PTEN 1
• VEGF 5
• AMPK 0
• TERT 3
• BRAF 1
• FGFR 1
• PRMT5 5
• CDK4/6 0
• HDAC 0
• HIF-1 1
• IL-6 0
• NRF2 0
• PSMA 4
• MYC 2
• COX-2 0
• CXCR4 0
• EZH2 0
• CD47 0
• HER2 2
• JAK 0
• MEK 0
• MET 1
• METTL3 0
• TLR4 0
• ATM 2
• GPX4 0
• MDM2 0
• BCL-2 0
• CDKN2A 0
• CTLA-4 0
• FAK 0
• HSP90 0
• JNK 0
• MMP-9 1
• TNF 0
• CD19 0
• NF1 1
• NTRK 1
• TREM2 0
• AR 0
• CD40 1
• HMGB1 0
• IDO1 0

EU-13 is a filter, not a ranking: it only narrows the list.

10 of 10+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  PARP Inhibition for Gliomas (PI-4G or π4g)

  NCT05297864· University of Oklahoma· Updated 23 May 2025

  “Funder terminated funding.”Registry text, quoted unchanged. Source

• Terminated

  18F-FluorThanatrace (PET/CT) in Glioblastoma

  NCT04221061· University of Pennsylvania· Updated 17 Jun 2024

  “Companion treatment trial closed early with negative results. No imaging study participants completed the full study imaging planned due to logistical difficulties.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

  NCT03749187· University of California, San Francisco· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 93
• Organoids 33
• Mendelian Randomization Analysis 14
• CRISPR-Cas Systems 11
• Gene Expression Profiling 150
• Sequence Analysis, RNA 10
• Exome Sequencing 2
• Proteomics 47
• Metabolomics 21
• Mass Spectrometry 9
• Flow Cytometry 16
• Immunohistochemistry 22
• Liquid Biopsy 10
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 224
• Positron-Emission Tomography 35
• Magnetic Resonance Imaging 231
• Machine Learning 265
• Deep Learning 42
• Cohort Studies 54
• Genome-Wide Association Study 13

See which targets of this disease your abstract mentions, and go to the people working on them.